GSK submits non-statistically significant NDA for Promacta

An FDA reviewer said that Promacta, an experimental platelet-boosting drug seeking an indication for acute treatment of chronic idiopathic thrombocytopenia purpura from GSK, did not help control bleeding any better than a placebo. The reviewer wrote:
“The data provided in this NDA (new drug application) do not demonstrate statistically significant, robust … treatment effect in decreasing [...]